With non-viral gene therapy in clinic, PBM-backed Xalud banks $30M series C 

Longtime investor PBM Capital has led Xalud’s $30 million series C round, enabling the company to continue its clinical work on a non-viral gene therapy for inflammatory disorders.

Diem Nguyen, CEO of New York City-based Xalud Therapeutics Inc., told BioCentury that PBM was the “primary investor” in Xalud’s series A and B rounds, beginning in 2015. Although she declined to give specific details, she said the series C round “had diversification in the investor pool” beyond PBM’s contribution. ...